Results 221 to 230 of about 1,723,944 (304)

TARGETING SIRTUIN 1 IN TYPE 2 DIABETES MELLITUS: A NOVEL APPROACH

ERA KARN, SUMAN BALA SHARMA, PREETI YADAV, THURAYA ABDULSALAM A.A. ALAZAZI, MONTEY NARUKA, NIRUPMA GUPTA, MANOJ KUMAR NANDKEOLIAR   +6 more
openalex   +1 more source

Association of Abatacept With Lower Mortality Risk Compared to Rituximab in Rheumatoid Arthritis–Associated Interstitial Lung Disease: An Emulated Target Trial

Arthritis &Rheumatology, EarlyView.
Objective The optimal treatment strategy for rheumatoid arthritis–associated interstitial lung disease (RA‐ILD) remains uncertain, and direct comparative data between biologics are limited. This study aimed to evaluate the effectiveness and safety of abatacept compared with rituximab in patients with RA‐ILD.
Po‐Cheng Shih, Shiow‐Ing Wang, Qing‐Wen Wang, James Cheng Chung Wei   +3 more
wiley   +1 more source

Reduced Methylation of IRF5 Gene as a Biomarker for Gestational Diabetes Mellitus. [PDF]

Med Sci Monit
Kunysz M, Cieśla M, Mora-Janiszewska O, Darmochwał-Kolarz D.   +3 more
europepmc   +1 more source

Mechanistic insights into psoriasis and type 2 diabetes mellitus comorbidity – Implications for treatment: A review

Ling Ouyang, Zhanzong Li, Yunhong Zeng
openalex   +2 more sources

A Randomized, Placebo‐Controlled Trial of Hydroxychloroquine in Incomplete Lupus

Arthritis &Rheumatology, EarlyView.
Objective Patients with features of systemic lupus erythematosus (SLE) who do not fulfill classification criteria can be designated as incomplete lupus erythematosus (ILE). This condition includes individuals with a high risk of progression to SLE. Treatment of ILE may reduce symptoms, severity, and incidence of SLE.
Nancy J. Olsen, Duanping Liao, Judith A. James, Joel M. Guthridge, Cristina Arriens, Diane Kamen, Mariko Ishimori, Daniel J. Wallace, Christopher Striebich, Sonali Narain, Benjamin F. Chong, Fan He, Eric W. Schaefer, Vernon M. Chinchilli, David R. Karp   +14 more
wiley   +1 more source

Emerging biomarkers for gestational diabetes mellitus and related pediatric outcomes. [PDF]

World J Clin Pediatr
Gautam T, Shamsad A, Singh R, Banerjee M.   +3 more
europepmc   +1 more source

Glucagon‐Like Peptide‐1 Receptor Agonists, Sodium‐Glucose Cotransporter‐2 Inhibitors, and Risk of Autoimmune Rheumatic Diseases

Arthritis &Rheumatology, Accepted Article.
Objective GLP‐1 receptor agonists (GLP‐1RAs) and SGLT2 inhibitors (SGLT2is) facilitate weight loss and exhibit immunomodulatory effects, but their impact on the risk of developing autoimmune rheumatic diseases (ARDs) is unclear. We compared ARD incidence following initiation of GLP‐1RAs, or SGLT2is, vs.
Derin Karacabeyli, Diane Lacaille, Na Lu, Hui Xie, J. Antonio Aviña‐Zubieta   +4 more
wiley   +1 more source

Hypoglycaemia and Cardiac Arrhythmias in Type 1 Diabetes Mellitus: A Mechanistic Review. [PDF]

J Pers Med
Mavromoustakou K, Fragoulis C, Cholidou K, Sotiropoulou Z, Anagnostopoulos N, Gastouniotis I, Lontou SP, Dimitriadis K, Thanopoulou A, Chrysohoou C, Tsioufis K.   +10 more
europepmc   +1 more source

The Relationship Between Aldose Reductase and Isoxazole Derivatives: An In Vitro and In Silico Approach to Its Correlation With Diabetic Conditions

Biotechnology and Applied Biochemistry, EarlyView.
ABSTRACT Diabetes mellitus (DM), which can result in a number of problems such as cataracts, neuropathy, retinopathy, nephropathy, and several cardiovascular illnesses, continues to be a growing issue despite major advancements in treatment approaches.
Ahmet Esat Göner, Hatice Esra Duran
wiley   +1 more source